(Q28371081)

English

ALK ALK Fusion G1202R

genetic variant

ALK FUSION G1202R
ALK FUSION GLY1202ARG
RS1057519783

In more languages

default values for all languages

No label defined

No description defined

edit

Statements

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/171

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/171

chromosome

human chromosome 2

genomic assembly

Genome assembly GRCh37

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/171

genomic start

29443613

genomic assembly

Genome assembly GRCh37

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/171

genomic end

29443613

genomic assembly

Genome assembly GRCh37

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/171

biological variant of

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/171

positive therapeutic predictor for

tanespimycin

medical condition treated

non-small-cell lung carcinoma

determination method

CIViC evidence level D

rating

CIViC 2-star trust rating

1 reference

1 August 2019

https://civic.genome.wustl.edu/links/evidence/1352

stated in

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers

negative therapeutic predictor for

crizotinib

determination method

CIViC evidence level D

rating

CIViC 4-star trust rating

medical condition treated

non-small-cell lung carcinoma

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/441

stated in

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers

ceritinib

determination method

CIViC evidence level D

rating

CIViC 4-star trust rating

medical condition treated

non-small-cell lung carcinoma

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/1345

stated in

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer

alectinib

determination method

CIViC evidence level D

rating

CIViC 3-star trust rating

medical condition treated

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/1350

stated in

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.

AP-26113

determination method

CIViC evidence level D

rating

CIViC 3-star trust rating

medical condition treated

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/1351

stated in

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.

crizotinib

determination method

CIViC evidence level C

rating

CIViC 3-star trust rating

medical condition treated

adenocarcinoma of the lung

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/1357

stated in

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers

Identifiers

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/171

dbSNP Reference SNP number

1 reference

ENST00000389048.3:c.3604G>A

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/171

NC_000002.11:g.29443613C>T

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/171

NM_004304.4:c.3604G>A

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/171

NP_004295.2:p.Gly1202Arg

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/171

(Q28371081)

ALK ALK Fusion G1202R

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)